» Articles » PMID: 26743881

Systemic Antifungal Therapy for Proven or Suspected Invasive Candidiasis: the AmarCAND 2 Study

Abstract

Background: In the context of recent guidelines on invasive candidiasis (IC), how French intensive care units (ICUs) are managing IC?

Methods: This is a prospective observational multicenter cohort study. During 1 year (2012-2013), 87 French ICUs enrolled consecutive patients with suspected or proven IC (SIC or PIC) and receiving systemic antifungal therapy (SAT). Data were collected up to 28 days after inclusion.

Results: We studied 835 patients, 291 with PIC and 544 with SIC. At SAT initiation, patients with SIC were significantly more severe (SAPS II 50.1 ± 18.7 vs. 46.2 ± 18.0). Severe sepsis or septic shock prompted to initiate empiric SAT in 70 % of SIC. Within 4 days in median, the initial SAT was modified in 49 % of patients with PIC vs. 33 % patients with SIC. Modifications were most often motivated by mycological results, and de-escalation was the most frequent change. Regarding compliance to IC management guidelines, echinocandin was used for 182 (62.5 %) patients with PIC, and 287 (52.7 %) of those with SIC; central venous catheter was removed in 87 (54.3 %) of patients with candidaemia, and 43 of the remaining patients received echinocandin; and de-escalation was undertaken after 5 days of SAT in 142 patients, after 10 days in 13 patients. As 20.6 % of SIC were secondarily documented, 403/835 (48 %) patients had finally a proven IC. Candida albicans was the main pathogen (65.3 %), then Candida glabrata (15.9 %). The 28-day mortality rates were 40.0 % in candidaemia, 25.4 % in cIAI, and 26.7 % in deep-seated candidiasis. In the overall population of patients with proven IC, four independent prognostic factors were identified: immunosuppression (Odds Ratio (OR) = 1.977: 1.03-3.794 95 % confidence interval (CI), p = 0.04), age (OR = 1.035; 1.017-1.053 95 % CI; p < 0.001), SAPS >46 on ICU admission (OR = 2.894; 1.81-4.626 95 % CI; p < 0.001), and surgery just before or during ICU stay (OR = 0.473; 0.29-0.77 95 % CI; p < 0.001).

Conclusion: When SAT is initiated in French ICUs, the IC is ultimately proven for 48 % of patients. Empiric SAT is initiated in severely ill ICU patients. The initial SAT is often adapted, with de-escalation to fluconazole when possible. Mortality rate remains high.

Citing Articles

Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions.

Novy E, Esposito M, Debourgogne A, Roger C J Fungi (Basel). 2025; 11(2).

PMID: 39997386 PMC: 11856068. DOI: 10.3390/jof11020091.


Establishment and Validation of a Machine-Learning Prediction Nomogram Based on Lymphocyte Subtyping for Intra-Abdominal Candidiasis in Septic Patients.

Zhang J, Cheng W, Li D, Zhao G, Lei X, Cui N Clin Transl Sci. 2025; 18(1):e70140.

PMID: 39835620 PMC: 11747989. DOI: 10.1111/cts.70140.


Predicting intra-abdominal candidiasis in elderly septic patients using machine learning based on lymphocyte subtyping: a prospective cohort study.

Zhang J, Zhao G, Lei X, Cui N Front Pharmacol. 2024; 15:1486346.

PMID: 39726780 PMC: 11669700. DOI: 10.3389/fphar.2024.1486346.


Empirical antifungal therapy for health care-associated intra-abdominal infection: a retrospective, multicentre and comparative study.

Mokart D, Boutaba M, Servan L, Bertrand B, Baldesi O, Lefebvre L Ann Intensive Care. 2024; 14(1):98.

PMID: 38916830 PMC: 11199462. DOI: 10.1186/s13613-024-01333-y.


Clinical Distribution and Drug Susceptibility Characterization of Invasive Isolates in a Tertiary Hospital of Xinjiang Province.

Zhang S, Zhang L, Yusufu A, Hasimu H, Wang X, Abliz P Infect Drug Resist. 2024; 17:1345-1356.

PMID: 38596533 PMC: 11001554. DOI: 10.2147/IDR.S450933.


References
1.
Morrell M, Fraser V, Kollef M . Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49(9):3640-5. PMC: 1195428. DOI: 10.1128/AAC.49.9.3640-3645.2005. View

2.
Eggimann P, Pittet D . Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med. 2014; 40(10):1429-48. PMC: 4176828. DOI: 10.1007/s00134-014-3355-z. View

3.
Charles P, Doise J, Quenot J, Aube H, Dalle F, Chavanet P . Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 2003; 29(12):2162-2169. DOI: 10.1007/s00134-003-2002-x. View

4.
Ostrosky-Zeichner L, Pappas P, Shoham S, Reboli A, Barron M, Sims C . Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2009; 54(1):46-51. DOI: 10.1111/j.1439-0507.2009.01756.x. View

5.
Cornely O, Bassetti M, Calandra T, Garbino J, Kullberg B, Lortholary O . ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012; 18 Suppl 7:19-37. DOI: 10.1111/1469-0691.12039. View